Background/Aims: There are many reports of non-alcoholic fatty liver disease (NAFLD) patients with increased carotid intima-media thickness (IMT). However, there is little information about carotid IMT in alcoholic fatty liver disease (AFLD) patients. We aimed to compare the carotid IMT of NAFLD patients and AFLD patients. Methods: The medical records of individuals who underwent carotid IMT measurement and abdominal ultrasonography between January 2006 and December 2008 at Korea University Ansan Hospital were retrospectively reviewed. The patients were divided into group A (no fatty liver without alcohol history), group B (NAFLD), group C (AFLD) and group D (no fatty liver with alcohol history). The carotid IMT results were compared across all groups. Results: The mean carotid IMT was 0.55 ± 0.1 mm for group A, 0.6 ± 0.1 mm for group B, 0.59 ± 0.1 mm for group C, and 0.54 ± 0.1 mm for group D. There were significant differences between groups A and B, groups A and C, and groups C and D (p < 0.05), but there were no differences between groups B and C (p = 0.736). Conclusions: We determined that patients with fatty livers have an increased carotid IMT both in NAFLD and AFLD patients.

1.
Farrell GC, Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99–S112.
[PubMed]
2.
Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, Cassader M: Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with adult treatment panel iii criteria in nonobese nondiabetic subjects. Diabetes Care 2008;31:562–568.
[PubMed]
3.
Sookoian S, Burgueno AL, Castano G, Pirola CJ: Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with adult treatment panel III criteria in nonobese nondiabetic subjects: response to Musso et al. Diabetes Care 2008;31:e42, author’s reply e43.
4.
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844–1850.
[PubMed]
5.
Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709–2716.
[PubMed]
6.
Simon A, Megnien JL, Levenson J: Coronary risk estimation and treatment of hypercholesterolemia. Circulation 1997;96:2449–2452.
[PubMed]
7.
Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C: Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991;134:250–256.
[PubMed]
8.
Sookoian S, Pirola CJ: Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008;49:600–607.
[PubMed]
9.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–2752.
[PubMed]
10.
MacSween RN, Burt AD: Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986;6:221–232.
[PubMed]
11.
Crabb DW: Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med 1999;48:184–188.
[PubMed]
12.
Lieber CS, Jones DP, Decarli LM: Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J Clin Invest 1965;44:1009–1021.
[PubMed]
13.
Vuppalanchi R, Chalasani N: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009;49:306–317.
[PubMed]
14.
Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G: Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54:3541–3546.
[PubMed]
15.
Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, Arcaro G: Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007;30:2119–2121.
[PubMed]
16.
Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A, Kato T, Okuda J, Ida K, Yoshikawa T: Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579–1584.
[PubMed]
17.
Aygun C, Kocaman O, Sahin T, Uraz S, Eminler AT, Celebi A, Senturk O, Hulagu S: Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2008;53:1352–1357.
[PubMed]
18.
Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G: Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006;29:1325–1330.
[PubMed]
19.
Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G: Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 2004;27:2498–2500.
[PubMed]
20.
Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E: Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005;25:1045–1050.
[PubMed]
21.
Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, Schminke U, Kessler C, John U: Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005;11:1848–1853.
[PubMed]
22.
Choi SY, Kim D, Kang JH, Park MJ, Kim YS, Lim SH, Kim CH, Lee HS: Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis (in Korean). Korean J Hepatol 2008;14:77–88.
[PubMed]
23.
Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G: Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42:473–480.
[PubMed]
24.
Fan AZ, Russell M, Dorn J, Freudenheim JL, Nochajski T, Hovey K, Trevisan M: Lifetime alcohol drinking pattern is related to the prevalence of metabolic syndrome. The Western New York Health Study (WNYHS). Eur J Epidemiol 2006;21:129–138.
[PubMed]
25.
Fuchs FD, Chambless LE, Folsom AR, Eigenbrodt ML, Duncan BB, Gilbert A, Szklo M: Association between alcoholic beverage consumption and incidence of coronary heart disease in whites and blacks: the atherosclerosis risk in communities study. Am J Epidemiol 2004;160:466–474.
[PubMed]
26.
Fuchs FD, Chambless LE, Whelton PK, Nieto FJ, Heiss G: Alcohol consumption and the incidence of hypertension: the atherosclerosis risk in communities study. Hypertension 2001;37:1242–1250.
[PubMed]
27.
Sung KC, Kim SH, Reaven GM: Relationship among alcohol, body weight, and cardiovascular risk factors in 27,030 Korean men. Diabetes Care 2007;30:2690–2694.
[PubMed]
28.
Riserus U, Ingelsson E: Alcohol intake, insulin resistance, and abdominal obesity in elderly men. Obesity (Silver Spring) 2007;15:1766–1773.
[PubMed]
29.
Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M: Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999;94:3010–3014.
[PubMed]
30.
Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G: The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol 1999;34:85–91.
[PubMed]
31.
Pourshams A, Malekzadeh R, Monavvari A, Akbari MR, Mohamadkhani A, Yarahmadi S, Seddighi N, Mohamadnejad M, Sotoudeh M, Madjlessi A: Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors. J Gastroenterol Hepatol 2005;20:229–233.
[PubMed]
32.
Torezan-Filho MA, Alves VA, Neto CA, Fernandes HS, Strauss E: Clinical significance of elevated alanine aminotransferase in blood donors: a follow-up study. Liver Int 2004;24:575–581.
[PubMed]
33.
Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the united states. Am J Gastroenterol 2003;98:960–967.
[PubMed]
34.
Ioannou GN, Boyko EJ, Lee SP: The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999–2002. Am J Gastroenterol 2006;101:76–82.
[PubMed]
35.
Bedogni G, Miglioli L, Masutti F, Castiglione A, Croce LS, Tiribelli C, Bellentani S: Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007;46:1387–1391.
[PubMed]
36.
Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, Bruno S, Mangano C, Polito I, Amato F, Cotichini R, Stroffolini T, Mele A: Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 2005;41:1151–1159.
[PubMed]
37.
Ruhl CE, Everhart JE: Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005;3:1260–1268.
[PubMed]
38.
Bizzaro N, Tremolada F, Casarin C, Bonetti P, Noventa F, Diodati G, Drago C, Realdi G: Serum alanine aminotransferase levels among volunteer blood donors: effect of sex, alcohol intake and obesity. Ital J Gastroenterol 1992;24:237–241.
[PubMed]
39.
Kondili LA, Taliani G, Cerga G, Tosti ME, Babameto A, Resuli B: Correlation of alcohol consumption with liver histological features in non-cirrhotic patients. Eur J Gastroenterol Hepatol 2005;17:155–159.
[PubMed]
40.
Maher JJ: Alcoholic steatosis and steatohepatitis. Semin Gastrointest Dis 2002;13:31–39.
[PubMed]
41.
Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1–10.
[PubMed]
42.
Kim HC, Kim DJ, Huh KB: Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009;204:521–525.
[PubMed]
43.
Lonardo A, Lombardini S, Scaglioni F, Ballestri S, Verrone AM, Bertolotti M, Carulli L, Ganazzi D, Carulli N, Loria P: Fatty liver, carotid disease and gallstones: a study of age-related associations. World J Gastroenterol 2006;12:5826–5833.
[PubMed]
44.
Mathiesen UL, Franzen LE, Aselius H, Resjo M, Jacobsson L, Foberg U, Fryden A, Bodemar G: Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002;34:516–522.
[PubMed]
45.
Hultcrantz R, Gabrielsson N: Patients with persistent elevation of aminotransferases: investigation with ultrasonography, radionuclide imaging and liver biopsy. J Intern Med 1993;233:7–12.
[PubMed]
46.
Joy D, Thava VR, Scott BB: Diagnosis of fatty liver disease: Is biopsy necessary? Eur J Gastroenterol Hepatol 2003;15:539–543.
[PubMed]
You do not currently have access to this content.